tirzepatide average weight loss first month What to Expect on Tirzepatide: Month-by-Month Timeline How Much Weight Can You

Most GLP1 side effects are GI-related (nausea, constipation) and improve as your body adjusts

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

While we need plenty of dietary antioxidants from varied and plentiful fresh fruits and vegetables, our most powerful antioxidant source is the glutathione our bodies produce

Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a new antidiabetic drug class with multiple metabolic effects

GLP-1 receptors (which respond to the GLP-1 we produce) are found in the pancreas, the gut, and in the brain, including in regions involved in dopamine signaling and addiction

It is designed to begin working when your blood sugar rises, and it promotes the pancreas releasing more insulin when blood sugar levels are up